ArticleBMC infectious diseases2025
Development and evaluation of novel Brucella diagnostic antigen protein ST.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundBrucellosis continues to pose a significant zoonotic challenge, necessitating the development of improved diagnostic solutions. This study innovatively integrates bioinformatics predictions with prokaryotic expression techniques to create novel diagnostic antigens for the detection of Brucella melitensis.
methodsOur study systematically analyzed four outer membrane proteins (OMP10, OMP25, VirB8, and VirB10). B-cell epitope prediction was conducted using the IEDB and ABCpred algorithms. A chimeric antigen was designed by fusing these four proteins in the sequence OMP10-OMP25-VirB8-VirB10. The recombinant protein was expressed in E. coli BL21(DE3) and purified using nickel-affinity chromatography. The diagnostic performance of the purified chimeric antigen was evaluated through indirect ELISA, utilizing 180 brucellosis sera, 20 healthy control sera, and 88 sera from other infections.
resultsIn our study, we successfully predicted and designed a novel recombinant Brucella diagnostic antigen protein, named OMP10-OMP25-VirB8-VirB10, referred to as the ST protein. We assessed its performance as a serological diagnostic biomarker for brucellosis using the indirect enzyme-linked immunosorbent assay. The results demonstrated that the ST protein exhibited a detection sensitivity of 98.33% and a specificity of 85.22%, with an AUC value of 0.9802.
conclusionThe ST protein, a fusion of four proteins derived from Brucella, demonstrates significant diagnostic potential in ELISA, offering a novel approach for the accurate diagnosis of brucellosis. This discovery provides an innovative perspective for enhancing early brucellosis screening in endemic regions. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.